Want to see SE:ICO full AI Analyst Report?
ICO Stock Chart & Stats
kr1.03
kr0.03(3.00%)
At close: 4:00 PM EDT
kr1.03
kr0.03(3.00%)
Day’s Range― - ―
52-Week Rangekr0.87 - kr2.16
Previous CloseN/A
Volume15.90K
Average Volume (3M)70.06K
Market Cap
kr104.35M
Enterprise Valuekr68.18M
Total Cash (Recent Filing)kr37.12M
Total Debt (Recent Filing)kr4.32M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding96,171,910
10 Day Avg. Volume100,969
30 Day Avg. Volume70,059
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)39.24
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.42
Revenue Forecast (FY)kr29.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong TTM revenue growth indicates that demand for Iconovo’s inhaled drug delivery work is expanding. If this growth continues, it can broaden the partnered project base and improve operating leverage, although profitability still needs to follow.
Low LeverageVery low leverage limits balance-sheet strain and preserves financial flexibility while Iconovo develops its pipeline. Compared with a highly indebted structure, this gives the company more capacity to withstand operating volatility and fund future priorities.
Proprietary Inhaler PlatformsA portfolio of proprietary inhaler platforms gives Iconovo reusable technology for developing new and generic inhaled products with pharmaceutical partners. This platform model can support multiple projects and diversify opportunities beyond a single product.
Bears Say
Persistent Operating LossesSubstantial EBIT and net losses show that the current revenue base is not covering the company’s cost structure. Continued losses can limit reinvestment capacity and make the business model dependent on successful project progression and eventual margin improvement.
Negative Cash GenerationMaterially negative operating and free cash flow means Iconovo is consuming cash rather than funding operations internally. If losses persist, this weakens financial resilience and increases the importance of future commercialization, milestones, or external funding.
Deteriorated MarginsThe shift from positive gross profit in 2024 to deeply negative gross profit in later periods signals that recent revenue growth has not translated into sustainable economics. Poor cost absorption remains a direct obstacle to achieving durable profitability.
ICO FAQ
What was Iconovo AB’s price range in the past 12 months?
Iconovo AB lowest stock price was kr0.87 and its highest was kr2.16 in the past 12 months.
What is Iconovo AB’s market cap?
Iconovo AB’s market cap is kr104.35M.
When is Iconovo AB’s upcoming earnings report date?
Iconovo AB’s upcoming earnings report date is Oct 23, 2026 which is in 12 days.
How were Iconovo AB’s earnings last quarter?
Iconovo AB released its earnings results on Aug 20, 2026. The company reported -kr0.098 earnings per share for the quarter.
Is Iconovo AB overvalued?
According to Wall Street analysts Iconovo AB’s price is currently Overvalued.
Does Iconovo AB pay dividends?
Iconovo AB does not currently pay dividends.
What is Iconovo AB’s EPS estimate?
Iconovo AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iconovo AB have?
Iconovo AB has 96,171,910 shares outstanding.
What happened to Iconovo AB’s price movement after its last earnings report?
Iconovo AB reported an EPS of -kr0.098 in its last earnings report. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of Iconovo AB?
Currently, no hedge funds are holding shares in SE:ICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iconovo AB
Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.